Amazon poised for strong Q2 earnings, driven by robust retail sales, favorable FX rates, and increasing demand for AI ...

Analysts downgraded Sarepta as FDA pause on Elevidys raises regulatory uncertainty, leading to significant stock pressure and valuation cuts.